Neurologic Complication
Conditions
Brief summary
The prevalence and typical patterns of neurological complications in hospitalized COVID-19 patients admitted to the intensive care units of the University Hospital Zurich will be investigated. The impact of neurological complications among COVID-19 patients on mortality, functional outcome, and organizational outcomes will be analyzed.
Detailed description
This study is a prospective observational cohort study to document prevalence and severity of neurological symptoms among patients requiring critical care admission for confirmed novel coronavirus disease (COVID-19). COVID-19 is classified as severe acute respiratory syndrome 2 (SARS-CoV-2) and shares significant structural and biological similarities with SARS-CoV, which has neuroinvasive properties and brainstem involvement. Early reports of COVID-19 progression indicate presence of severe neurological complications, including seizures, coma, encephalitis, and cerebrovascular events including ischemic stroke, intracranial hemorrhage, and cerebral venous sinus thromboses. In addition, recent data from Zika-virus and H1N1 influenza pandemics reveal a high incidence of neurological complications, including Guillain Barré syndrome and neonatal microcephaly for Zika-virus and narcolepsy with H1N1 infections. Early reports from China suggest neurological symptoms may occur in approximately 36% of SARS-CoV-2 positive patients, with increased prevalence among more severe cases, and fall into three categories: central nervous system symptoms or diseases, peripheral nervous system symptoms, and skeletal muscular symptoms. However, the exact prevalence of these conditions and impact on patient disease severity and outcomes is unknown. As the incidence and severity of COVID-19 infection continues to rapidly rise on an international level, it is imperative to capture prospective data to accurately document prevalence, severity and clinical characterization of neurological components of COVID-19, the influence of treatment regimens of neurological complications, and role of these confounders on patient and organizational outcomes.
Interventions
OTHERfurther processing of health data
further processing of biological materials and health related personal data for research
Sponsors
Emanuela Keller
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adults (age \> 18 years old) treated at ICUs * Admitted with confirmed COVID-19 infection * Patient exhibiting acute neurological manifestations * General consent of the Institute of Intensive Care Medicine available from patient or legal representative
Exclusion criteria
* Pre-existing severe neurologic dysfunction
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Prevalence of neurological complications | through study completion, on an average of 3 weeks | Determine the prevalence of neurological complications in hospitalized COVID-19 patients admitted to the intensive care unit. |
| Prevalence and outcome of severe neurological complications | through study completion, on an average of 3 weeks | Examine if empiric COVID-19 therapies are associated with difference in the prevalence and outcome of severe neurological complications of COVID-19. |
| Impact of neurological complications | through study completion, on an average of 3 weeks | Determine the impact of neurological complications among COVID-19 patients on mortality, functional outcome, and organizational outcomes (ICU length of stay, hospital length of stay) among patients with confirmed COVID-19. |
| Characteristic patterns in cerebral imaging and electroencephalography (EEG), as well as cerebrospinal fluid (CSF) | through study completion, on an average of 3 weeks | Analyze characteristic patterns in cerebral imaging and electroencephalography (EEG), as well as cerebrospinal fluid (CSF) of patients, in whom a lumbar puncture has been performed for clinical reasons |
| Brain for pathological changes and histopathological findings (if patient dies). | through study completion, on an average of 3 weeks | Analyze the brain for pathological changes and histopathological findings, if the patient dies. |
Countries
Switzerland
Outcome results
None listed